← Back to Company DatabaseVisit Website
Singlera Genomics
Methylation-based early cancer detection from blood samples.
Series C+La Jolla, CAFounded 2014
About
Singlera Genomics develops early cancer detection tests using DNA methylation analysis of cell-free DNA in blood. The company's proprietary technology can detect multiple cancer types at early stages with high sensitivity. With operations in both the US and China, Singlera is focused on making cancer screening widely accessible.
Total Funding
$240MKey Product
ColonES colorectal cancer screening testGeography
North AmericaKey Investors
Panacea VentureLegend CapitalGP Capital
Focus Areas
Early Detection / ScreeningDiagnostics
Technology
Liquid BiopsyGenomics / Sequencing
Cancer Types
ColorectalLungPan-cancer
Last updated: Feb 4, 2026